呼吸系统疾病,归因于流感,呼吸道合胞病毒(RSV),和SARS-CoV-2,在2023/2024呼吸道病毒季节期间在全国范围内报道。新型SARS-CoV-2变体的出现被认为是导致COVID-19病例增加的重要因素。约翰霍普金斯医院系统(JHHS)的数据显示,肠道病毒/鼻病毒也以很高的速度传播。分析最流行的呼吸道病毒的临床结果对于理解循环病毒基因型的作用至关重要。对SARS-CoV-2,流感,RSV,或2023年6月1日至12月31日之间的肠道病毒/鼻病毒纳入研究.剩余的临床样品用于靶向病毒全基因组测序和基因分型。研究了患者感染后的元数据和结果,按病毒变体和基因型分层。12月SARS-CoV-2阳性的增加与JN.1的优势有关。18岁以下患者的入院主要与肠道病毒/鼻病毒和RSV相关。而年龄较大的人群主要与SARS-CoV-2和流感感染有关。12月,与SARS-CoV-2相关的入院人数随着JN.1变体的优势而增加。流感亚型的入院人数没有显着差异,鼻病毒物种,或观察到SARS-CoV-2变体。与RSVB相比,RSVA的入院几率略高。我们的数据突出了系统分析呼吸道病毒感染以告知公共卫生策略和临床管理的重要性。特别是当SARS-CoV-2成为地方病时。这些发现强调了扩大基因组监测在阐明病毒进化的临床意义中的价值。重要意义对2023/2024呼吸道病毒季节早期多种共同循环呼吸道病毒的流行病学和临床结果的分析突出了SARS-CoV-2JN.1变体的出现,并强调了肠道病毒/鼻病毒在呼吸道感染中的重要性。了解这些动态对于完善公共卫生策略和临床管理至关重要。特别是当SARS-CoV-2转变为流行状态时。这项工作强调了持续监控的必要性,鲁棒的诊断算法,和详细的基因组分析,以预测和减轻呼吸道病毒感染的负担,最终有助于在医疗保健环境中做出更明智的决策和更好的患者预后。
Respiratory disease, attributed to influenza, respiratory syncytial virus (RSV), and SARS-CoV-2, was reported nationally during the 2023/2024 respiratory viral season. The emergence of novel SARS-CoV-2 variants was considered a significant factor contributing to the rise in COVID-19 cases. Data from the Johns Hopkins Hospital System (JHHS) showed that
enterovirus/rhinovirus had also been circulating at high rates. Analyzing clinical outcomes of the most prevalent respiratory viruses is crucial for understanding the role of circulating viral genotypes. A retrospective cohort of patients who tested positive for SARS-CoV-2, influenza, RSV, or
enterovirus/rhinovirus between 1 June and 31 December 2023 was included in the study. Remnant clinical samples were utilized for targeted viral whole-genome sequencing and genotyping. Patients\' metadata and outcomes following infection were studied, stratified by viral variants and genotypes. The increase of SARS-CoV-2 positivity in December was associated with the predominance of JN.1. Admissions for patients under 18 years old were primarily associated with
enterovirus/rhinovirus and RSV, while older age groups were mainly linked to SARS-CoV-2 and influenza infections. SARS-CoV-2-related admissions increased with the predominance of the JN.1 variant in December. No significant difference in admissions for influenza subtypes, rhinovirus species, or SARS-CoV-2 variants was observed. RSV A was associated with slightly higher odds of admission compared with RSV B. Our data highlight the importance of systematically analyzing respiratory viral infections to inform public health strategies and clinical management, especially as SARS-CoV-2 becomes endemic. The findings highlight the value of expanded genomic surveillance in elucidating the clinical significance of viral evolution.IMPORTANCEThe analysis of the epidemiology and clinical outcomes of multiple co-circulating respiratory viruses in the early 2023/2024 respiratory virus season highlights the emergence of the SARS-CoV-2 JN.1 variant as well as underscores the importance of
enterovirus/rhinovirus in respiratory infections. Understanding these dynamics is essential for refining public health strategies and clinical management, especially as SARS-CoV-2 transitions to an endemic status. This work emphasizes the need for ongoing surveillance, robust diagnostic algorithms, and detailed genomic analyses to anticipate and mitigate the burden of respiratory viral infections, ultimately contributing to more informed decision-making in healthcare settings and better patient outcomes.